MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.

MLA

Lai, Catherine, et al. “MYC Gene Rearrangement in Diffuse Large B-Cell Lymphoma Does Not Confer a Worse Prognosis Following Dose-Adjusted EPOCH-R.” Leukemia & Lymphoma, vol. 59, no. 2, Feb. 2018, pp. 505–08. EBSCOhost, https://doi.org/10.1080/10428194.2017.1339882.

APA

Lai, C., Roschewski, M., Melani, C., Pittaluga, S., Shovlin, M., Steinberg, S. M., Dunleavy, K., Pack, S., Jaffe, E. S., & Wilson, W. H. (2018). MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R. Leukemia & Lymphoma, 59(2), 505–508. https://doi.org/10.1080/10428194.2017.1339882

Chicago

Lai, Catherine, Mark Roschewski, Christopher Melani, Stefania Pittaluga, Margaret Shovlin, Seth M Steinberg, Kieron Dunleavy, Svetlana Pack, Elaine S Jaffe, and Wyndham H Wilson. 2018. “MYC Gene Rearrangement in Diffuse Large B-Cell Lymphoma Does Not Confer a Worse Prognosis Following Dose-Adjusted EPOCH-R.” Leukemia & Lymphoma 59 (2): 505–8. doi:10.1080/10428194.2017.1339882.